|Product:||Undisclosed HuCAL-derived, fully human antibody|
|Other:||This antibody is the third HuCAL-derived antibody to enter clinical trials in 2010. Morphosys will receive a milestone payment from Novartis in connection with the initiation of this trial.
The german company projects that in 2010 between four and six partnered programs could enter clinical trials. With the recently announced in-licensing of an Fc-engineered antibody against CD19 from Xencor Inc., MorphoSys now expects up to 15 proprietary and partnered antibody programs to be in clinical trials by year-end, at least four of which should be in phase 2.